← Back to Clinical Trials
Recruiting NCT04119908

NCT04119908 Videomicroscopy for the Prediction of Bleeding in Constitutional Haemorrhagic Diseases

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04119908
Status Recruiting
Phase
Sponsor University Hospital, Lille
Condition Von Willebrand Diseases
Study Type INTERVENTIONAL
Enrollment 400 participants
Start Date 2023-05-24
Primary Completion 2028-05-24

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Sublingual videomicroscopyblood sample

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 400 participants in total. It began in 2023-05-24 with a primary completion date of 2028-05-24.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

In Willebrand disease, there is currently no test available to identify non-invasively patients with a high risk of bleeding from angiodysplasias The study propose to use a sublingual capillary bed analysis by video-microscopy, a sensitive, reproducible and non-invasive technique, to assess whether sublingual capillary density is predictive of hemorrhagic risk for patients with von Willebrand disease.

Eligibility Criteria

Inclusion Criteria: * Adult patient with a significant form of von Willebrand disease (according to the inclusion criteria of the Willebrand Disease French Reference Center), a Glanzmann Thrombasthenia, a moderate to severe Haemophilia A or a woman carrying the hemophilia gene * Social insured patient Exclusion Criteria: * Minor patient * Refusal of consent * Person benefiting from a system of legal protection * Pregnant patient

Contact & Investigator

Central Contact

Antoine Rauch, MD,PhD

✉ antoine.rauch@chru-lille.fr

📞 3 20445962 (poste 29673)

Principal Investigator

Antoine Rauch, MD,PhD

PRINCIPAL INVESTIGATOR

University Hospital, Lille

Frequently Asked Questions

Who can join the NCT04119908 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Von Willebrand Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04119908 currently recruiting?

Yes, NCT04119908 is actively recruiting participants. Contact the research team at antoine.rauch@chru-lille.fr for enrollment information.

Where is the NCT04119908 trial being conducted?

This trial is being conducted at Lille, France.

Who is sponsoring the NCT04119908 clinical trial?

NCT04119908 is sponsored by University Hospital, Lille. The principal investigator is Antoine Rauch, MD,PhD at University Hospital, Lille. The trial plans to enroll 400 participants.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology